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Abstract 
Mesoporous matrices of different pore size and chemical composition were explored as potential 
delivery matrices for the broad spectrum bacteriocin, nisin A. The adsorption of nisin A onto two 
mesoporous silicates (MPS - SBA-15, MCM-41) and two periodic mesoporous organosilanes (PMO - 
MSE, PMO-PA) was examined. It was found that hydrophobic interactions dominated in the 
adsorption of this peptide to the matrices, lending the highest adsorption to MCM-41 with a small 
pore size of 2.8 nm. The hydrophobic ethylene-bridged MSE (6 nm pore) improved the loading and 
protection of nisin A from degradation by a non-specific protease pepsin, over un-functionalised 
SBA-15 which had a slightly larger pore size and less hydrophobic moieties. Nisin A did not adsorb 
onto an amine-functionalised PMO. Upon suspension in modified fasted state simulated gastric fluid 
(pH 1.6), the highest release of nisin A was observed from MCM-41, with a lower release from SBA-
15 and MSE, with release following Higuchi release kinetics. No release was detected into modified 
fasted state simulated intestinal fluid (pH 6.5) but despite this, the suspended matrices loaded with 
nisin A remained active against Staphylococcus aureus. 
1.0 - Introduction 
The current antimicrobial resistance (AMR) crisis has been fuelled by the overuse or misuse of 
antibiotics thereby exposing pathogenic bacteria to sub-inhibitory levels of antibiotics, inducing 
resistance. The rise in AMR has also been attributed to the prevalence of antibiotic use in agriculture 
and household products [1]. The prevalence of resistance in strains such as Streptococcus 
pneumoniae, Mycobacterium tuberculosis, methicillin-resistant Staphylococcus aureus (MRSA) and 
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multidrug-resistant Gram-negative bacteria has resulted in the reduced effectiveness of certain 
antibiotics. This results in life-threatening infections, particularly nosocomial infections where the 
patient’s immune system is compromised [2]. Novel antimicrobial agents are required to meet the 
reduced effectiveness of current drug treatments to combat the rise in antibiotic resistance among 
pathogenic bacteria [2]. However, as outlined in a recent World Health Organisation report, there are 
very few new classes of antimicrobials in the pipeline against drug-resistant clinical pathogens [3]. 
Bacteriocins are one potential class that has shown promising activity against antimicrobial drug-
resistant infections due to their potency and specificity [3]–[6]. 
Bacteriocins are antimicrobial peptides produced by bacteria to inhibit competing bacterial strains. 
There have been a number of bacteriocins to date identified with activity against clinically relevant 
Gram-positive and Gram-negative bacteria, including bacterial strains which have shown resistance to 
other drug treatments such as MRSA, S. pneumonia, Clostridium difficile, vancomycin-resistant 
enterococci (VRE) and various mycobacteria [7]–[9]. They are ribosomally synthesised and generally 
hydrophobic peptides which inhibit related bacterial strains. However, these antimicrobial peptides 
are subject to many issues such as proteolytic degradation in vivo, low solubility and unfolding and 
aggregation during storage and formulation [10]. Therefore, modification of these bacteriocins or the 
development of suitable delivery matrices is necessary to increase their stability. Nisin A (3.4 kDa) is 
a bacteriocin produced by the Gram-positive lactic acid bacterium (LAB), Lactococcus lactis subsp. 
lactis and is classed as a lantibiotic, due to the presence of lanthionine rings within its’ chemical 
structure. Nisin A is FDA-approved as a food additive (E234) and certified as a GRAS (Generally 
Regarded as Safe) excipient. It has also shown activity against pathogenic bacterial strains including 
S. aureus, Escherichia coli, S. pneumoniae, Enterococcus faecium and C. difficile, indicating its 
potential for clinical applications [11]–[13]. In addition to its antimicrobial activity, nisin A has also 
shown immunomodulatory, spermicidal and anticancer activity [14]–[16]. However, the susceptibility 
of nisin A to proteolytic degradation by intestinal enzymes such as trypsin and α-chymotrypsin, along 
with poor solubility at certain pH’s have hindered its’ use as an antibiotic treatment [17]–[19]. While 
there have been some attempts at improving the solubility and stability of nisin A for pharmaceutical 
applications, none have yet resulted in an FDA-approved dosage form of this antimicrobial [20]–[26].  
To improve the stability of nisin A as a food preservative, it has to date been encapsulated in 
liposomes [27], layered double hydroxides [28] and in numerous polymeric matrices (e.g. chitosan, 
alginate [29]). While the controlled release of nisin A from these matrices was achieved, evidence for 
protection from enzymatic degradation is limited. The protective nature of polymeric/hydrogel drug 
delivery matrices has been previously reported for oral protein delivery [30] [31]. Marschutz & 
Bernkop-Schnurch examined the protection of insulin against luminally secreted enzymes, i.e. trypsin 
& chymotrypsin in vitro also using polymeric delivery systems. These delivery systems contained 
polymer-inhibitor conjugates which showed strong inhibitory activity towards degradation of the 
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hormone by these enzymes [32]. The adsorption/encapsulation approach using these hydrogels is 
generic and the resulting matrix would be the same for delivery of any peptide or protein, limiting the 
ability to tailor the delivery matrix for a peptide of a particular size, chemical functionality, activity or 
instability. This limits the application of these polymeric matrices to proteins or peptides with 
particular physicochemical properties. 
Mesoporous silica (MPS) matrices have previously been used to deliver drug molecules and have also 
been applied in the areas of bone regeneration, tissue engineering and bio catalysis [33]–[36]. 
Organic-inorganic hybrid mesoporous matrices, such as periodic mesoporous organosilanes (PMOs), 
have also been well documented as delivery matrices for small molecules [37] with control over the 
rate of the release of these small molecules being reported. PMO’s differ from post functionalised or 
co-condensed mesoporous silicates, where the organic moiety is grafted onto a mesoporous silica 
matrix or a silica precursor such as tetraethoxy silane is co-condensed with an organically 
functionalised triethoxysilane group respectively. PMO’s are formed by using an organically bridged 
silica precursor which ensures that the organic group is homogeneously distributed throughout the 
matrix and reduces any risk of phase separation. Although it depends on the nature of the organic 
bridging group, in general, they appear to have a lower haemolytic effect and a higher 
biocompatibility with cells than pure mesoporous silica matrices [37]. The advantages of using these 
mesoporous matrices in drug delivery include 1) homogenous distribution of the drug due to the well-
ordered porous structure, 2) ease of appropriate organic group functionalisation throughout the matrix 
and 3) tuning of the pore size, particle size and morphology [37], [38]. Mesoporous matrices have 
been explored as a potential oral delivery matrix for the enhanced oral bioavailability of poorly 
soluble drugs, improved dissolution of active pharmaceutical ingredients (API’s) in different pH 
environments [39][40][41][42]. Thus from our previous work on enzyme immobilisation, we now 
propose that mesoporous silicates (MPS) and periodic mesoporous silanes (PMO) can be designed as 
an oral delivery platform to host specific peptides or proteins by tuning their pore size and chemical 
composition to optimise the interaction between the matrix and the peptide and obtain the optimal 
loading, release profile and level of protection from enzymatic degradation. 
In this study, MPS, SBA-15 [43] and MCM-41[43] (pure silica) and PMO matrices, PMO-PA (amino-
functionalised) [44] and MSE (ethylene-functionalised) [45] , with pore sizes in the range 2.8-6.8 nm, 
were studied for their potential to adsorb nisin A and protect it against proteolytic degradation. The 
adsorption properties of nisin A onto each matrix were explored and the rate of release and activity of 
nisin A from the porous matrices were analysed. The release of nisin A from the matrices in simulated 
gastrointestinal media with and without exposure to a degrading protease, and the activity of the nisin 
A loaded mesoporous particles after prolonged exposure to gastrointestinal media were examined. 
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2.0 Experimental Section 
2.1.0 Materials 
Nisin A (95% from Lactococcus lactis in sauerkraut) was obtained from Handary, Belgium. 
Trifluroacetic acid (TFA, ≥ 99%), acetonitrile (ACN, ≥ 99.9%), sodium taurocholate (NaTc, ≥ 95%), 
potassium phosphate monobasic (KH2PO4,  ≥ 99%), L-ɑ-lecithin (≥ 99%, from egg yolk), potassium 
chloride (KCl, ≥ 99%), hydrochloric acid (HCl, 36.5-38%), acetic acid (99.8-100.5%), sodium citrate 
dihydrate (≥ 99.0%), citric acid monohydrate (≥ 99.0%), calcium chloride hexahydrate (CaCl2.6H2O, 
98%), Tetraethoxysilane (TEOS), bis[3-(trimethoxysilyl)propyl]amine (≥ 90%), 1,3,5-
trimethylbenzene (98%), sodium hydroxide (NaOH), ethanol (EtOH), methanol (MeOH), Pluronic 
P123, Pluronic F127, bis(trimethoxysilyl)ethane (BTMSE), cetyltrimethylammonium bromide 
(CTAB), bovine serum albumin > 98%, brain heart infusion agar and broth (BHI) were all obtained 
from Sigma Aldrich Ireland Ltd. Tris base (≥ 99.8%) was purchased from Fisher Scientific Ireland. 
Sodium acetate was purchased from VWR International Ltd (Ireland). Deionised (DI) water was 
obtained from an Elga PURELAB System. S.aureus (strain 20231) was purchased from the German 
collection of microorganisms and cell cultures, DSMZ. 
2.2.1 – Preparation of MPS matrices 
SBA-15 [43], MSE [45], MCM-41 [43] and PMO-PA [44] were synthesised as previously reported 
and may be found in the supplementary information. 
2.2.2 - Characterisation of MPS matrices  
Scanning electron microscopy (SEM), transmission electron microscopy (TEM), attenuated total 
reflectance Fourier transform infra-red (FTIR) and powder x-ray diffraction (P-XRD) analyses is 
presented in supplementary information. 
Solid state nuclear magnetic resonance (SSNMR) analysis was carried out on a Bruker 400 MHz 






H respectively using 4 
mm ZrO2 rotors. Optimisation of the magic angles was carried out by spinning a rotor packed with 
potassium bromide (KBr) at 5 kHz. Samples were spun at 10 kHz. The low field peak of adamantane 
(38.48 ppm) was used as a reference for 
13
C chemical shifts. 
13
C cross-polarisation magic angle 
spinning (CPMAS) spectra were recorded using a contact time of 1-1.5 ms and a recycle delay of 3 s. 
1024 scans were collected per sample. Glycine was used to check the signal to noise ratio. The low 





Si MAS spectra were recorded using a recycle delay of 200 s with 50 kHz line 
broadening. 300-500 scans were collected per sample. All experiments were conducted with proton 
decoupling. For SBA-15 and MCM-41, the relative quantities of Qn species were determined by 
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deconvolution of the 
29
Si spectra into 3 Gaussian lines using the deconvolution tool in Bruker 
TopSpin version 3.5pl7. 
2.2.3 HPLC analysis of Nisin A 
Reverse phase high performance liquid chromatography (RP-HPLC) was used to quantitatively and 
qualitatively analyse nisin A, using a similar method to Slootweg et al [19]. Analytical RP-HPLC of 
nisin A was carried out on an Agilent 1260 Infinity system with UV-vis detection operating at 214 nm 
with a Purospher STAR RP-18 end-capped Hibar (C18 15cm x 4.6 mm, 5 µm) column. The mobile 
phase consisted of 0.1% TFA (buffer A) and ACN containing 0.1% TFA (buffer B) using a gradient 
of 75:25 to 55:45 (A/B) over 52 minutes. The chromatographic profile of nisin A showed three peaks 
(corresponding to the intact nisin A, a modified/oxidised nisin A and a fragment of nisin A). The 
quantification of nisin A for the loading and release studies was based on the signal from the intact 
nisin only (Fig. 1, signal B). In order to fractionate the three nisin A components, RP-HPLC analysis 
was performed on a Kinetix LC-HPLC column (150 x 4.6 mm, 2.6 µm, 100Å) using a gradient of 
28:72 to 57:43 (A/B) over 35 minutes. MALDI-TOF MS analysis was carried out on fractions of 
interest using an Axima TOF2 MALDI TOF mass spectrometer (Shimadzu Biotech, Manchester, 
UK). 0.5 µL matrix solution (α-cyano-4-hydroxycinnamic acid; 10 mg/mL in buffer A) was deposited 
onto the target for 5 seconds, then removed. The residual solution was allowed to air-dry and 0.5 µL 
of the fractions of interest were deposited onto the coated targets. 0.5 µL of matrix solution was added 
on top of the deposited sample and allowed to air-dry. The sample was analysed in positive-ion 
reflectron mode. 
2.2.4 Nisin A loading onto MPS matrices 
2.2.4.1 Initial loading studies 
Nisin A solutions (500 µg/mL) were prepared in citrate buffer (100 mM, pH 4.01) or KCl/HCl buffer, 
(677 mM, pH 2). Mesoporous matrices (10,000 µg/mL; MCM-41/SBA-15/MSE/PMO-PA) were 
added to the nisin A solution and the nisin A solution without MPS matrices was used as a control. 
Samples were sonicated until a suspension was formed. While stirring, 15 x 1 mL samples of each 
mesoporous matrix suspension with nisin A and the nisin A controls were transferred to Eppendorf 
tubes and placed on a rocker at 37 °C. After 0.5 h, three tubes of each sample and a control were 
removed from the rocker, centrifuged (5000 rpm, 15 min) and the supernatants analysed for nisin A 
content by RP-HPLC. This was repeated at 1, 3, 6 and 21 h. The amount of nisin A adsorbed to the 
mesoporous matrices was then calculated by subtracting the concentration of nisin A in the 
supernatant from the initial nisin A concentration in solution as determined from the calibration curve. 
The loading was given in terms of µg of nisin A per mg of mesoporous matrix. 
2.2.4.2 Adsorption Isotherms: 
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Nisin A solutions were prepared at concentrations of 500, 1000, 2000, and 3000 µg/ml in 677 mM, 
pH 2 HCl/KCl buffer. 5 mg of each silicate (MSE, MCM-41, and SBA-15) was added to 1ml of nisin 
A solution and to 1 ml of buffer (as a control). The tubes containing the silicates and controls of free 
nisin A at each concentration were incubated at 37°C with shaking of 250 rpm for 5 hours, after which 
they were centrifuged for 15 minutes at 1,500 rpm. The supernatant was analysed using RP-HPLC to 
determine the concentration of nisin A remaining in solution. 
Using the data obtained from the adsorption to the 5mg of silicate, the adsorption study was scaled up, 
whereby 100 mg of SBA-15, MSE or MCM-41, were weighed into tubes, and 20 ml of a 2,000 µg/ml 
nisin A solution was added. The tubes were again shaken at 37°C at 250 rpm for 5 hours. They were 
subsequently centrifuged, at 5,000 rpm for 15 minutes and the supernatant analysed for nisin A 
content using RP-HPLC, the pellets were washed with 5 ml of DI water and centrifuged and the pellet 
wash was also analysed by RP-HPLC. 
The adsorption isotherms were fitted to linearised versions of the Langmuir and Freundlich adsorption 
isotherm theories (equation 1 and equation 2 respectively) and the Langmuir constants for the 
adsorption coefficient (K) and monolayer surface coverage (C) (equation 1) and the Freundlich 
constants m and a (equation 2) were determined [46], [47]. 
   
  
 




   
    Equation 1 
   (                    Equation 2 
Where Ceq is the equilibrium concentration of nisin A in solution (μg/ml) and Cs is the loading of nisin 
A onto the matrix (mg/g). 
2.2.5 IC50 of nisin A against S. aureus  
S. aureus was cultured overnight at 37°C in BHI broth and subsequently diluted to an OD of 0.1. 
Nisin A was dissolved in a KCl/HCl buffer at pH 2 at a concentration of 500 μg/ml. 200 μl of a 
bovine serum albumin (BSA) solution at a concentration of 0.1% in PBS was added to the wells of a 
96-well microtitre plate and incubated for 30 minutes at 37°C to prevent adherence of the nisin A to 
the walls of the plate. The BSA was removed and the wells were rinsed with PBS. Varying volumes 
of the nisin A solution (0.5 mg/ml) were diluted with PBS and added to the S. aureus culture (150 μl) 
to give a final volume of 200 μl and nisin A concentrations of 10, 12, 15 and 20 µg/ml. Controls of 
BHI broth (200 μl broth), KCl/HCl buffer (44 μl with 150 μl culture), and 150 μl S. aureus with 50 μl 
PBS were added to the plate. The plate was incubated overnight at 37°C in a Biotek ELx808 Ultra 
microplate reader (Mason Technologies, Dublin), with readings taken every 30 minutes at 590 nm for 
the 24 hour period. The blank readings were subtracted from the test results, and the median IC50 was 
  
 7 
determined based on the concentration that killed 50% of the culture based on the positive control 
(150 μl S. aureus with 50 μl PBS). 
2.2.6 In vitro release study 
Modified Fasted State Simulated Gastric Fluid (m-FaSSGF) was prepared by combining 36 ml 1 M 
sodium chloride, (NaCl), 40 ml 1 mM sodium taurocholate (NaTc), 12.5 ml 1M hydrochloric acid 
(HCl), 2 ml 5 mM L-α-lecithin. The solution was made up to 500 ml with DI water and the pH was 
confirmed to be 1.6 [48], [49]. Modified Fasted State Simulated Intestinal Fluid (m-FaSSIF) was 
prepared with 68.62 mM NaCl, 34.3 mM NaOH, 19.12 mM maleic acid, 0.2 mM lecithin, and 1.618 
mM porcine bile extract, the pH was confirmed to be 6.5. There were no enzymes present in the 
media used for the release studies [48], [49].  
Based on the loading onto each matrix, approximately 1-2 mg of nisin A was added to 1 ml of 
dissolution media by adjusting the amount of loaded matrix added – thus, 5.08 mg of MCM-41-nisin 
(1,120 μg/ml nisin A as it had a loading of 0.282 mg/g), 33.6 mg SBA-15-nisin (1,820 μg/ml nisin A 
as it had a loading of 0.0573 mg/g), and 7.14 mg MSE-nisin (1,320 μg/ml nisin A as it had a loading 
of 0.2277 mg/g), were suspended in 1 ml each of m-FaSSIF and m-FaSSGF with controls comprising 
of 5.08 mg of MCM-41, 33.6 mg SBA-15, and 7.14 mg MSE, and nisin A solutions of 2,000 μg/ml, 
200 μg/ml, and 20 μg/ml, and incubated at 37°C shaking at 275 rpm. Samples were centrifuged at 
7,000 rpm for 7 minutes and the supernatant was fully removed at time points of 2, 4, 24, 48 and 72 
hours, and replenished with fresh media. The samples were analysed using RP-HPLC to determine the 
concentration of nisin A present in the supernatant. 
The release data was fitted to different release rate equations to theoretically determine the mode of 
release of nisin A from the matrices. The data was fitted to the zero order (Eq. 3), first order (Eq. 4), 
Hixon-Crowell (Eq. 5) and the simplified Higuchi (Eq. 6) equations, and the best fit was determined 
by the regression of the linear plot (R
2
). The release rate constant (K0, K, KHC or KH) was 
subsequently determined from the plots produced [50]. 
Qt = Q0 + K0t     Equation 3 
Ln Qt = Ln Q0 + Kt/2.303   Equation 4 
3                  Equation 5 
Qt = KHt1/2      Equation 6 
Where Q0 indicates the initial concentration of drug (µg/ml), ‘Qt’ indicates cumulative drug release 
(%) at time ‘t’, and time ‘t’ refers to time in hours. 
2.2.7 In vitro antimicrobial activity study 
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A release study was also conducted as described above into m-FaSSIF/m-FaSSGF under sterile 
conditions, whereby the nisin solution was filter sterilised through a 0.2 µm PES filter, and the MPS 
matrices were UV irradiated for 30 minutes. 5 mg of unloaded SBA-15, MSE and MCM41, 5 mg 
nisin A loaded silicates SBA-15-nisin (0.0775 mg/g, thus 359.6 µg/ml nisin A), MSE-nisin (0.0971 
mg/g, thus 442.5 µg/ml nisin A), MCM-41-nisin (0.0923 mg/g, thus 422.5 µg/ml nisin A) and nisin A 
(400 µg/ml), were incubated in m-FaSSIF/m-FaSSGF (1 ml) at 37ºC shaking at 250 rpm for 4 hours.  
The activity of both the supernatant and the pellet from the m-FaSSIF and m-FaSSGF release study 
was assessed. S. aureus was cultured overnight in brain heart infusion broth (BHI) and diluted to an 
optical density (OD595) of 0.1. After the 4 hour release, the samples were centrifuged at 13,500 rpm 
for 7 minutes, and 100 µL supernatant was added to 3 ml of the culture. The pellet was also re-
suspended in 3 ml of the culture. For the control, 1 ml of the free nisin A solution (400 µg/ml) in 
FaSSIF was added to 2 ml of culture. The samples were incubated for 4 hours, alongside controls of 
blank silicates and free nisin A (n=3). After this incubation period, the pellets were centrifuged at 
4000 rpm for 15 minutes, and serial dilutions of the supernatant were prepared using PBS and plated 
onto BHI plates (n=4). The plates were incubated at 37ºC overnight and the colonies were counted 
and reported in colony forming units per ml (CFU/ml). 
2.2.8 Activity of digested nisin A with S. aureus 
In order to determine the activity of nisin A degraded by proteolytic enzyme activity, three 5 ml 
samples of a 1,000 µg/ml nisin A solution prepared in KCl buffer at pH 2 in the presence and absence 
of pepsin (1 % w/v) and a solution of 1 % w/v pepsin in KCl pH 2 buffer, were incubated at 37°C for 
exactly 24 hours. After 24 hours, 5 ml of 10% trifluoroacetic acid (TFA) was added to each sample to 
halt further enzyme activity. Each sample was subsequently filter sterilised (0.22 μm, PES filter) and 
2 ml of each sample was incubated with 3 ml of a S.aureus culture (OD = 0.1) for 4 hours. Serial 
dilutions were prepared in PBS and plated on BHI plates. Colonies were counted after 24 hours at 
37°C and expressed in CFU/ml. 
2.2.8.1 Effect of proteolytic enzymes on nisin A adsorbed to MPS matrices  
In order to determine the protection offered by the silicates from proteolytic enzymes, a nisin A 
solution with a concentration of ~ 1,000 µg/ml was prepared in KCl/HCl pH 2 buffer.  Mesoporous 
silicates SBA-15, MSE and MCM-41 loaded with nisin A were added to three tubes such that the 
nisin A concentration present in the tube corresponded to approximately 1,000 µg/ml. To the loaded 
silicates, 2.5 ml of a 1% pepsin solution in KCl/HCl was added. Controls of nisin A loaded silicates in 
pH 2 buffer and free nisin A in both pepsin and pH 2 buffer were run alongside the test samples, each 
in triplicate. All solutions were shaken at 37ºC for 24 hours, after which 2.5 ml of 10% trifluoroacetic 
acid (TFA) was added to each tube to halt further enzyme activity. The samples were analysed using 
RP-HPLC to quantify the nisin A present in solution. The pellets were re-suspended in 2.5 ml m-
FaSSGF and shaken at 37°C for 24 hours to de-sorb the remaining nisin A. The samples were 
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centrifuged at 3900 rpm for 10 minutes, and the supernatant for each sample was analysed by RP-
HPLC.   
2.2.9 Estimation of molecular dimensions 
A file corresponding to the structure of pepsin (5PEP) was downloaded from the protein database 
(http://www.rcsb.org/pdb). The structure for nisin A was not available alone and was only available as 
its complex with lipid II, a key complex in the active mechanism of antimicrobial peptides, as 
previously determined by solution NMR (1WCO). Thus the structure was modified and the ligand 
was removed [51]. The files were viewed using PyMOL (version 2.1.1) and the dimensions were 
obtained using the Measuring Wizard function in PyMol. 
3.0 Results and Discussion 
The hypothesis for this work was that ordered porous matrices could protect small peptides from 
degradation by larger proteases in the gastrointestinal tract and that the order and size of the pores and 
the chemical composition of the matrices could be optimised to get the optimal loading, protection 
and release rate of the peptide in vivo. It was hypothesised that smaller pore sizes would protect nisin 
A from enzymatic degradation and that the chemical functional groups would increase the loading of 
nisin A onto a particular delivery matrix. It was not clear from in silico studies of nisin A which 
chemical functionality on the matrix would dominate the adsorption and release processes and thus, 
experimental data on the loading and the rate of release of nisin A from the mesoporous matrices into 
modified fasted state simulated gastric fluid (m-FaSSGF) and modified fasted state simulated 
intestinal fluid (m-FaSSIF) was collected in an attempt to predict the pharmacokinetics of the nisin A 
formulations in vivo. 
3.1 Characterisation of Nisin A  
HPLC analysis of the as-received nisin A showed the presence of three main components (Fig. 1) with 
molar masses (Mw) of 3370, 3352 and 3152 Da, in order of elution (Fig. 1, inset). The first component 
to elute (A) was identified as Ser
33
-nisin (Mw = 3370 Da), where residue 33 is genetically encoded as 
serine, thus the serine has not been converted to Dha in this variant [52]. The second component (B) 
corresponded to that of intact nisin A (Mw = 3352 Da) and the final component (C) was identified as 
the nisin A fragment (1-32) (nisin
1-32
, Mw = 3152 Da), in which both the dehydroalanine and the 
lysine at the C-terminal are cleaved, as reported by Lian et al [53]. All three components appeared to 
adsorb or release from the matrices studied during this work at the same measurable rate. 
The molecular dimensions of nisin A were estimated to be 4.76 nm x 2.32 nm x 0.9 nm and pepsin 
was estimated to have the dimensions 5.60 nm x 5.54 nm x 4.14 nm. These dimensions for nisin A as 
measured using PyMOL simply provide a rough estimate of the molecular size and shape of nisin A. 
Nisin A most likely adopts a different conformation (Fig. 2) in gastrointestinal fluid in the absence of 
  
 10 
lipid II but the available structural data gives an estimate of the maximum length of the molecule. The 
estimated surface potential was determined using the ‘generate vacuum electrostatic function’ in 
PyMol. The surface potential was estimated to determine the potential for hydrophobic or electrostatic 
interactions between the enzymes/peptide, and the mesoporous particles. As with the molecular 
dimensions, the estimated surface potential of nisin A (Fig. 2) is also an estimate deduced from this 
conformation. The isoelectric point (pI) of nisin A is approximately 8.8 which means that in m-
FaSSGF at pH 1.6 and in pH 2 buffer, it would carry a net positive charge [54]. Pepsin has an 
isoelectric point of 2.2-3.0 [55] and thus would carry a much lower net positive or neutral charge at 
pH 1.6 or 2. However, the estimated surface potential shows significant areas of positive, negative and 
neutral charge on both pepsin and nisin. This would indicate that they could interact with a surface 
through electrostatic or hydrophobic interactions. Nisin A would likely be more attracted to a 
negatively charged surface than the pepsin. In fact, pepsin appears to have large areas of negative 
charge from the estimated surface potential which could reduce its adsorption to a negatively charged 
surface. Pore sizes of approximately 3 nm are likely to accommodate nisin A molecules but prevent 
the entry of the larger, globular protease molecules such as pepsin, trypsin and chymotrypsin. The 
selective adsorption of nisin A to porous matrices would ideally protect nisin A against degradation 
by such proteases.  
3.2 Characterisation of mesoporous matrices 
Porous delivery matrices with amine, hydroxyl groups and hydrophobic patches were previously 
synthesised and characterised by our group [44], [56]. Here, these materials were further characterised 
using solid state NMR (SSNMR) as well as using typical scanning and transmission electron 
microscopy, X-ray diffraction, nitrogen adsorption and attenuated total reflectance Fourier transform 
infra-red (FTIR) analysis. The physicochemical properties of the mesoporous matrices are presented 
in Table 1.  
The average pore diameters for SBA-15, PMO-PA and MSE were comparable (6.8, 5.9 and 6.0 nm 
respectively) with MCM-41 presenting a narrower pore diameter (2.8 nm). The broad pore size 
distribution for PMO-PA can be attributed to the disordered porous array of this material, as 
confirmed by TEM and P-XRD analysis (supplementary material) The irregular shape of the PMO-
PA particles made it difficult to determine the average particle size by SEM but the other three 
materials had particle size distributions in the sub-micron range with MCM-41 being the smallest by 
far with an average particle size of ~170 nm (Table 1).  
The chemistry of each matrix was characterised by FTIR and SSNMR spectroscopy. The amine-
functionalisation of PMO-PA was confirmed by the presence of the N-H stretch at 3328 cm
-1
 and the 
N-H bending at 1641 cm
-1 
in the FTIR spectrum. The ethylene-functionalisation of MSE was 
confirmed by the C–H deformation vibrations at 1276 and 1418 cm
-1
 (data not shown) [57]–[59]. 
13
C 
CPMAS SS-NMR analysis of the four mesoporous matrices confirmed the chemical functionalisation 
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of each material (Fig. 3a). MSE had one peak at a chemical shift (δ) of 5.3 ppm, corresponding to the 
ethyl carbons. For the PMO-PA material, three peaks were present at 10.2, 20.1 and 50.8 ppm, 
corresponding to the three environments for the amino propyl bridging carbons. The peak furthest up 
field most likely corresponds to the carbons bound to silicon, with the peak at 20.1 ppm 
corresponding to the carbons bound to other carbons and the peak downfield from that at 50.8 ppm 
corresponding to the carbons bound to the amino groups, due to deshielding of carbon by the more 
electronegative nitrogen atoms. Similar signals were observed by Hartono et al for their 
aminopropyltriethoxysilane functionalised silicates [60]. Thus, the organic functional groups, -CH2-
CH2- and –CH2-CH2-CH2-NH-CH2-CH2-CH2- were successfully incorporated into the silica matrices 
for MSE and PMO-PA respectively. The 
13
C CPMAS spectrum of SBA-15 and MSE showed small 
signals (δ ≈ 59 ppm, 15 ppm) indicating the presence of a small amount of residual surfactant (P123), 
undetected by ATR-FTIR. 
 
29
Si SS-NMR was also used to confirm functionalisation of MSE and PMO-PA and can distinguish 
between siloxane species (Si(OSi)n(OH)4-n, Qn) and organosiloxane species (Tn).  The peaks at δ = -90 
to -120 ppm in the 
29
Si-NMR spectra of all four matrices correspond to the Qn species (Fig. 3b). Three 
peaks are present in this range corresponding to siloxane bridges (SiO4, Q4), silanol ((SiO)3SiOH, Q3) 
and geminal silanol ((SiO)2Si(OH)2, Q2) silicon species [61]. For MSE and PMO-PA, an additional 
set of peaks at δ = -50 to -70 ppm was present in the 
29
Si-NMR spectra, corresponding to the Tn 
species present as a result of organic functionalisation periodically dispersed throughout the matrix 
[62]. The peaks in the Qn region and the Tn region were integrated to approximate the ratio Qn to Tn 
species (Table 2). From this calculation, roughly 94 % of Tn type silicon atoms exist in MSE, i.e. 
those bound to ethane groups, with a small percentage (6 %) bound to other silicon atoms via a 
siloxane bridge (Qn species, present as a broad peak) which may arise from Si-C bond cleavage during 
synthesis. The PMO-PA material contained 30 % Tn type silicon species, i.e. those bound to the 
propyl amine functional groups, and 70 % Qn type silicon species. Both MCM-41 and SBA-15 
contained Qn type silicon species only, as expected. The chemical structures for all of the materials 




Si NMR spectra (Fig. 3c-e). While MCM-41 and SBA-15 
are both pure mesoporous silicates, the surfactant is removed by calcination for MCM-41 (necessary 
to ensure complete removal of the CTAB surfactant, a toxic chemical) and by Soxhlet extraction for 
SBA-15 (to remove the non-toxic Pluronic surfactant P123). From deconvolution of the Qn species in 
the spectra into 3 Gaussian lines, the proportion of silanol species (Q3 and Q2) was found to be 
reduced in MCM-41, compared to SBA-15 as a result of calcination (Table 2) giving MCM-41 
proportionately more  hydrophobic adsorption sites than SBA-15. 
From previously published data, the isoelectric points of the mesoporous matrix particles are reported 
(Table 1)[44], [56], [54], [55], [63]. At pH 2, MCM-41, SBA-15 and MSE are all just below their 
isolectric point and thus will have a low positive surface charge. At pH 2, the amine-functionalised 
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silica, PMO-PA, would be strongly positively charged due to the presence of the amino propyl 
bridging groups and the higher isoelectric point of this MPS (pI 9.1) [44].  
3.3 Adsorption Studies 
Based on isoelectric points, it was hypothesised that at pH 2, MCM-41, SBA-15 and MSE would 
adsorb more nisin A (pI = 8.8) than the more positively charged PMO-PA. Nisin A solutions were not 
particularly stable at pH 7 and so adsorption studies were not conducted at this pH. MCM-41 had a 
significantly smaller pore diameter than either SBA-15 or MSE, 2.8 nm versus 6.0 nm and 6.8 nm. 
Thus, the pores of MCM-41 should be impenetrable by pepsin (5.60 nm x 5.54 nm x 4.14 nm), the 
proteolytic enzyme used in this study, but nisin A with its smaller dimensions (4.76 nm x 2.32 nm x 
0.9 nm) may be able to diffuse through its hexagonal porous network. The pores of MSE, PMO-PA 
and SBA-15 are large enough to allow pepsin to diffuse to some extent into their porous network, and 
potentially degrade any nisin A that it can reach. 
From the initial adsorption studies, nisin A did not adsorb onto PMO-PA at pH 2-4 but adsorbed 
significantly onto MCM-41, SBA-15 and MSE. When these latter three matrices were incubated with 
solutions of increasing nisin A concentration at pH 2, up to 3000 µg/mL, MCM-41 reached a 
maximum loading of nearly 400 µg/mg while lower loadings were observed onto both MSE and 
SBA-15. From the adsorption isotherms data (table 3), nisin A is bound more strongly to MCM-41 
than MSE and the binding to SBA-15 is the weakest. The isotherms also indicate that at higher 
concentrations of nisin A, higher loadings onto SBA-15 are observed. However, at concentrations of 
2500 µg/ml nisin A or higher, precipitation of the nisin A was observed in the controls. This 
aggregate formation, potentially even induced earlier than in the control by the heterosurface 
presence, meant that when the equilibrium concentration of nisin was greater that 2500 µg/ml, an 
accurate loading could not be determined. The adsorption isotherms (Fig. 4) indicate that more nisin 
A binds to MCM-41 than to MSE. In addition, the binding of nisin A to SBA-15 appears to be quite 
weak at lower nisin A concentrations. From the study carried out, maximum loadings of 0.0976 + 
0.0002 mg/g onto SBA-15, 0.258 + 0.002 mg/g onto MSE, and 0.391 + 0.005 mg/g onto MCM-41 
were obtained.  
By fitting the adsorption data to linear models of the Langmuir and Freundlich theories (Table 3) it 
was found that the MCM-41 and MSE could load significantly higher amounts of nisin A compared to 
SBA-15 with MCM-41 exhibiting the highest adsorption coefficient (K). From the adsorption 
isotherm theories, it appeared that nisin A adsorbs predominantly through hydrophobic interactions - 
with adsorption onto the SBA-15 surface being weaker than onto MCM-41 or MSE, most likely due 
to the scarcity of hydrophobic moieties on its surface. No nisin A is absorbed onto PMO PA due to 
the combination of PMO-PA’s hydrophilic and highly positively charged surface. 
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It appears the smaller pore size and higher proportion of hydrophobic siloxane bridges of the MCM-
41 compared to SBA-15 promoted adsorption of the peptide to the matrix. These factors increased the 
strength of the interaction and the overall loading onto MCM-41. Given that both SBA-15 and MCM-
41 have a similar chemical composition, this data implies that the pore size and the relative number of 
siloxane bridging groups in the matrix have a large effect on the strength of binding and loading 
capacity of a mesoporous matrix for nisin A. The presence of the  ethylene bridging groups 
homogeneously dispersed in the periodic mesoporous organosilane structure of MSE increased the 
hydrophobicity of the matrix, and this strengthened the interaction between nisin A and the surface of 
MSE as well as increasing the loading, compared to SBA-15. Pore volumes showed no correlation 
between the loading and the available pore volume for each matrix, Table 1. From the loadings of 
nisin A, up to 400 mg/g on MCM-41 which is the equivalent of ~0.12 µmole/g, the nisin A molecules 




, using the dimensions suggested 
earlier for each nisin molecule, 4.76 nm x 2.32 nm x 0.9 nm. Thus there is a high excess of pore 
volume available on all the mesoporous matrices and pore volume does not influence loading. 
It has previously been suggested in the literature that the adsorption of a range of small molecule 
pharmaceuticals onto SBA-15 was best described by the Freundlich equation [64]. A similar trend 
was observed here for nisin A onto SBA-15 (Table 3) where it is clear that the Freundlich theory fits 
the adsorption of nisin A to SBA-15 better, with an R
2
 value of 0.937. The percentage adsorption onto 
SBA-15, MSE and MCM-41 was not affected by scaling up to 20 ml and it was noted that the 
components of the nisin A being used were adsorbed/desorbed at the same rate i.e. there was no 
preferential adsorption of any of the individual nisin A components (Fig. 1). 
3.4 In vitro release and activity studies 
The median inhibitory concentration (mIC50) of nisin A against S.aureus was determined to be ~ 10 
μg/ml over a period of 24 hours at 37°C (Fig. 6). The mIC50 of nisin A against S. aureus was 
determined in order to ensure that an effective inhibitory concentration of nisin A was adsorbed onto 
the mesoporous materials for studying their in vitro bioactivity. The rate of release of nisin A from the 
mesoporous matrices into both modified fasted state simulated gastric fluid (m-FaSSGF) and 
modified fasted state simulated intestinal fluid (m-FaSSIF) was carried out in an attempt to predict the 
pharmacokinetics of the nisin A formulations in vivo. Since the rate of dissolution of mesoporous 
silica matrices in aqueous solution is extremely slow, the release of nisin A from these matrices is 
primarily due to dissociation from the surface of the matrix or diffusion out of the pores [65].  
After 5 h in m-FaSSGF, a burst release of ~10 % and ~ 2 % nisin A was observed from MSE and 
SBA-15 respectively, with release from MSE levelling off at ~14 % (Fig. 5). Nisin A continued to 
release from SBA-15 gradually up to 72 hours. Nisin A release from MCM-41 was faster, with a 
release of ~ 21 % after 5 hours and over 28 % by 72 hours. Over 72 % of the loaded nisin A remained 
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adsorbed to all three matrices despite immersion for 72 hours in both m-FaSSGF and m-FaSSIF. The 
burst release of nisin A observed from the matrices into m-FaSSGF could be due to nisin A at the 
surface dissociating from these matrices, followed by the slow diffusion from inside the porous matrix 
as seen previously for the release of drugs from unfunctionalised silica matrices [34], [66]. The higher 
cumulative release from MCM-41 in this media compared to SBA-15 may be due to the smaller 
particle size of MCM-41, with its shorter pores resulting in smaller diffusion distances, as well as the 
increased external surface area of the MCM-41 particles which could posess a greater concentration 
of surface adsorbed nisin A. Additionally, in this release study, the loading per mg of MCM-41 and 
MSE were much higher than the SBA-15 loading which can influence the dissolution profile. Further 
studies are being conducted to probe the influence of loading on the dissolution profile of nisin A 
from MSE. Conversely, MCM-41 showed the highest release and adsorption indicating that the nisin 
A may be interacting with the MCM-41 through hydrophobic interactions, thus showing increased 
dissociation. This is similar to the release of LL-37, another cationic AMP, at pH 7.4 from silanol rich 
silica matrices with pore sizes of 3.1-3.5 nm observed by Braun et al [67].  
The in vitro release data into m-FaSSGF from all three matrices was found to best fit Higuchi’s 
release model (Supplementary Material). This is similar to several previously reported drug release 
kinetics studies from mesoporous matrices [68]. The Higuchi model describes release kinetics which 
slow as the diffusion path or the distance that the drug molecules have to travel increases [50]. This 
finding supports the hypothesis that the burst release observed from the data sets indicates the 
presence of surface adsorbed nisin A which dissociated from the surface upon suspension in the m-
FaSSGF, followed by a slower diffusion of nisin A from the pores of the mesoporous matrices. No 
release of nisin A was detected by RP-HPLC analysis from SBA-15, MSE or MCM-41 into m-
FaSSIF over this time period, due to the poor solubility of nisin A at the pH of the m-FaSSIF (pH 
6.5). 
The activity of the supernatants and pellets against S. aureus was studied. During the activity assays, 
all of the nisin A loaded matrices and their supernatants in m-FaSSGF completely inhibited the 
growth of S. aureus. The activity of the pellets from the m-FaSSIF release showed that the silicate 
pellets showed an 8 log10 reduction, 8 log10 reductions and 9 log10 reductions (SBA-15-nisin, MSE-
nisin, and MCM-41-nisin respectively (Fig. 7)). The m-FaSSIF supernatant showed no killing of the 
bacterial culture after the 4 hour time period, with no decrease in colony forming units per ml based 
on the positive control (n=4). No inhibition was observed from the m-FaSSIF or the blank silicate 
(supernatant or pellet) controls (n=4). The activity exhibited by the MSE-nisin and the SBA-15-nisin 
pellet was comparable, with the MCM-41-nisin pellet showing slightly higher inhibitory activity. The 
activity shown by the pellets indicates that the nisin A loaded mesoporous particles themselves were 
active when dispersed near the bacteria, presumably due to the diffusion of the bacterial cells toward 
the active particles, and the slow release of the bacteriocin from these matrices. This activity from the 
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pellets could be advantageous when administered near the site of infection and provide protection 
from any degrading enzymes in the intestinal tract. 
3.5 Protection of Nisin A Offered by Mesoporous Matrices 
The protection offered by the mesoporous matrices was tested with pepsin. Quantification post 
incubation with pepsin showed that ~21 % of intact nisin A remained in solution after the 24 hour 
period, in comparison with the control of nisin A at pH 2 for 24 hours in the absence of pepsin.  
The protection offered by SBA-15, MSE and MCM-41 was then determined by suspending nisin A 
loaded MPS matrices in a pepsin solution. After 24 hour incubation, the concentration of intact nisin 
A in the supernatant decreased by 54.4 %, 43.1 % and 41.9% from SBA-15-nisin, MSE-nisin and 
MCM-41-nisin, respectively compared to release into the KCl/HCl pH 2 buffer without pepsin (Table 
5). After re-suspension in m-FaSSGF, the MSE-nisin showed a higher release of intact adsorbed nisin 
A, in comparison to the nisin release from the MCM-41. It is possible that either (i) pepsin had 
degraded more of the nisin A adsorbed in the MCM-41 and SBA-15 matrices or (ii) the pepsin 
molecules adsorbed to the surface of the MCM-41 and SBA-15, blocking diffusion of nisin A from 
the pores. In any case, no intact nisin A was diffusing into the m-FaSSGF media from SBA-15 which 
would reduce its antimicrobial potential.  
The pore size is likely a defining factor in terms of protection based on the molecular dimensions of 
the pepsin as previously discussed. However as indicated by the results, surface functionality is also 
an influential aspect. The MSE has slightly smaller pore size than the SBA-15 (6.0 nm) and contains 
hydrophobic residues (-CH2-CH2-) which may contribute to the increased protection in comparison to 
the SBA-15. The interaction of pepsin with the matrices needs to be further probed to establish if a 
high affinity of the proteases for the matrix reduces or enhances the antimicrobial activity of the nisin 
A loaded matrix. Thus, with regard to protecting the peptide against enzymatic degradation, reducing 
the pore size and increasing the hydrophobicity of the matrix improved protection of nisin A against 
pepsin.  
4.0 Conclusions 
The adsorption properties of nisin A onto four different mesoporous matrices were explored and the 
rate of release of nisin A from the porous matrices was analysed. Chemical functionality and pore size 
had a large influence on loading, release rate, activity and protection from enzymatic degradation. The 
loaded matrices and the released nisin A were both found to exhibit antimicrobial activity. 
Specifically, the bacteriocin, nisin A, can be successfully adsorbed onto pure silica and ethylene-
functionalised but not amine-functionalised silica matrices. Unfunctionalised calcined silica with a 
small pore size (< 3nm) exhibited the strongest binding, the highest loading, and offered the peptide a 
high degree of protection from enzymatic degradation in bio-relevant media. Conversely, a more 
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hydrophobic periodic mesoporous organosilane exhibited a lower loading but offered a similar degree 
of protection with a higher release of intact nisin A after exposure to pepsin. Thus a mesoporous 
matrix can be designed, in terms of its pore dimensions and its chemical functionality, to control the 
loading, the rate of release and the stability of a particular bacteriocin into bio-relevant media. This 
antimicrobial formulation strategy could be used for a wide range of bacteriocins. It is predicted that 
depending on the surface properties and size of the peptide, a more/less hydrophilic or larger/smaller 
pore matrix could be formulated to optimise the loading, release and protection offered by the porous 
matrix. Thus mesoporous silica-based matrices offer potential as a novel formulation approach for 
bacteriocins and could potentially enable their development into novel antimicrobial medicines.  
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Figure 1. RP-HPLC chromatogram of Nisin A (1 mg/mL) with MALDI-TOF weight 










Figure 2. Structures and estimated surface potentials at pH 7 (extracted from the Protein 
DataBank (PDB) and viewed using PyMOL) of (a) pepsin (5PEP), and (b) nisin A (1WCO, 












From top to bottom: (a) 
13
C CPMAS spectra for PMO-PA, MSE, MCM-41 and 
SBA-15, (b) 
29
Si MAS spectra of PMO-PA, MSE, MCM-41 and SBA-15 and chemical 










Figure 4. Adsorption isotherm of nisin A onto SBA-15, MSE and MCM-41 at pH 2 (677 









Figure 5. Percentage release of nisin from SBA-15-nisin (1.82 mg nisin A available), MSE-
nisin (1.32 mg nisin A available), and MCM-41-nisin (1.12 mg nisin A available) into 1 ml m 










Figure 6. Antimicrobial activity of nisin A against S.aureus at concentrations of 10, 12 & 15 












Figure 7. The activity of nisin-loaded matrices against S. aureus, free nisin (174 μg), 
supernatants and pellets from the m - FaSSIF release study. The silicates; SBA-15, MSE and 











Table 1. Summary of the properties of the as-synthesised mesoporous silica matrices. 
*Calculated from BJH desorption curve of adsorption isotherm 
 
Table 2. Relative abundance of Qn and Tn Si species in MPS, approximated by integration on 
single pulse 
29














SBA-15 100 0 ~40 ~46 ~14 
MCM-41 100 0 ~60 ~32 ~8 
MSE 6 94 - - - 
PMO-PA 70 30 - - - 
 
 
Table 3 Parameters obtained by fitting the nisin adsorption to SBA-15, MSE and 
MCM-41 data to Langmuir and Freundlich linearized isotherms. The measure of fit to 
the model is indicated by the R2 value. 
Mesoporous Matrix Langmuir Freundlich 
 K C (mg/g) R
2



























MCM-41 2.8 0.31 2.2 702 ± 1 0.13 ± 0.02 ~ 3.5
[52]
 
SBA-15 6.8 1.14 6.2 748 ± 8 1.2 ± 0.04 ~ -3.5 
[52]
 
MSE 6.0 0.91 6.3 816 ± 14 0.94 ± 0.16 ~ 3.5 
[52]
  





MCM-41-nisin 0.034 385 0.999 0.225 79.4 0.647 
MSE-nisin 0.008 323 0.998 0.239 50.1 0.975 
SBA-15-nisin 0.0005 213 0.73 0.608 1 0.937 
 
 
Table 4 Calculated Higuchi constants for the in vitro release kinetics from SBA-15-
nisin, MSE-nisin and MCM-41-nisin. 
Mesoporous Matrix Model of Best Fit Equation R
2
 Higuchi Constant (KH) 
SBA-15-nisin 




MSE-nisin 0.74 0.85 
MCM-41-nisin 0.90 1.59 
 
 
Table 5 The percentage protection of nisin A by mesoporous matrices based on the 
difference between detection of nisin A in KCl/HCl with and without pepsin (1% w/v). 
 SBA-15-Nisin MSE-Nisin MCM-41-Nisin 
Mass of nisin A loaded matrix added 49.9 + 1.4 mg 37.4 + 0.3 mg 36.9 + 0.5 mg 
Total nisin A present 4,590 + 130 µg 4,281 + 31 µg 4,341 + 48 µg 
Released in 1.0% w/v pepsin in 
KCl/HCl, 24 hours, at 37°C 570.5 + 46.3 µg 355.6 + 17.1 µg 472 + 127.6 µg 
Typical release into KCl/HCl, 24 hours, 
at 37°C 
1,252 + 220 µg 625.5 + 63.4 µg 811.7 + 80 µg  
The percentage decrease in intact 
nisin in pH 2 KCl/HCl after 24 hours 
exposure to pepsin. 
54.4 % 43.1 % 41.9 % 
Released in m - FaSSGF after exposure 
to 1% pepsin at the 48 hour timepoint, 
at 37°C 
Not detectable 641 + 12 µg 232 + 22 µg 
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